School of Medicine
Showing 1-10 of 70 Results
Professor of Biomedical Data Science and of Statistics
Current Research and Scholarly InterestsStatistical models and reasoning are key to our understanding of the genetic basis of human traits. Modern high-throughput technology presents us with new opportunities and challenges. We develop statistical approaches for high dimensional data in the attempt of improving our understanding of the molecular basis of health related traits.
Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics
Current Research and Scholarly InterestsWe investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.
Kathleen M. Sakamoto
Shelagh Galligan Professor in the School of Medicine
Current Research and Scholarly InterestsMy research focuses on the molecular pathways that regulate normal and aberrant blood cell development, including acute leukemia and bone marrow failure syndromes. We are also studying novel drugs for treatment of cancer.
Associate Professor of Biomedical Data Science, of Biochemistry and, by courtesy, of Statistics
Current Research and Scholarly Interestsstatistical computational biology focusing on splicing, cancer and microbes
Peter L. Santa Maria, MBBS, PhD
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsWe study chronic suppurative otitis media, a chronic biofilm infection of the middle ear predominantly involving pseudomonas and staph aureus. We are investigating mechanisms of sensory hearing loss, host microbe interactions and trialling novel therapeutics.
Our work in tympanic membrane regeneration has entered clinical trials.
Novel treatments for wound healing in intra oral wounds with potential applications to prevent post tonsillectomy wound healing and oral mucositis.
Kavita Sarin, MD, PhD
Associate Professor of Dermatology
Current Research and Scholarly InterestsMy research encompasses two main areas: 1) Using next-generation RNA, whole genome, and exome sequencing, we are investigating the genetic alterations involved in skin cancer progression, response to therapy, and other clinical outcomes and 2) We are developing and implementing genome-wide genetic risk prediction assessments for skin cancer into clinical use and studying the impact of this information on patient care.
Professor of Microbiology and Immunology
Current Research and Scholarly InterestsOur laboratory studies virus-host interactions with an emphasis microRNA-mediated gene regulation and on translational control. The mechanism by which a liver-specific microRNA regulates hepatitis C virus genome replication is under intense scrutiny. In addition, the mechanism of internal ribosome entry in certain cellular and viral mRNAs and its biological role in growth and development is being investigated.
Assistant Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
We previously developed genome sequencing technologies that enable epigenetic studies in primary human immune cells from patients: 1) 3D enhancer-promoter interaction profiling (Nat Genet, 2017), 2) paired epigenome and T cell receptor (TCR) profiling in single cells (Nat Med, 2018), 3) paired epigenome and CRISPR profiling in single cells (Cell, 2019), and high-throughput single-cell ATAC-seq in droplets (Nature Biotech, 2019). We used these tools to study fundamental principles of the T cell response to cancer immunotherapy (PD-1 blockade) directly in cancer patient samples (Nature Biotech, 2019; Nat Med, 2019).